In a small laboratory in the heart Korean Institute In Paris, French chemist Raphaël Rodriguez It works on what can become one of the most important medical breaches in the battle against cancer. While he may have failed in his first year at the Medical College, Rodriguez did not abandon his ambition to save lives. Today, a team leads discovered a weakness In biological driving mechanisms TumorThe process with which cancer is spread through the body – almost responsible 70 percent of cancer -related deaths.
Heart of the immune system against metastasis
Rodriguez’s research focuses on a certain set of cells in The immune system Known as Walker. Under normal conditions, these cells help protect the body by attacking the stirred invaders. But in the presence of cancer, some of the billionaires are subjected to a shift. According to RodriguezThey begin to “adopt a program that helps cancer cells to emigrate and invade new tissues, and become actually partners in the spread of cancer.
This transformation is not only behavior, however Metabolism. The team discovered that these The supporter of the tumor Its internal operations are converting in a way that supports the development of cancer. This insight allowed Rodriguez and its colleagues to design a molecule that can interfere with the specified metabolic key. By targeting these rogue baccalaureate, the molecule works to reflect its role in supporting a malignant tumor without damaging other healthy immune cells.
A new way to treat cancer
Rodriguez developed this molecule in cooperation with researchers through multiple specialties, including chemistry, cell biology and immunity. Experiments before clinical uses mice showed that the molecule not only prevents the shift of the curses but also It slows the development of metastatic tumors. This multi -step approach opens a way towards treatments that not only fight the primary tumor, but also prevent cancer from spreading completely.
The effects of this work attracted attention from the main drug groups and cancer research institutions all over the world. Rodriguez is now preparing for the next stage: Bringing this molecule Clinical test. Although this process is long and complex, its results have already given great interest in the scientific community. His work is closely followed, especially since fighting a malignant tumor is still one of the most urgent challenges in oncology.
From his laboratory in Korean InstituteOne of the leading centers in Europe Cancer Research, Rodriguez continues to improve his approach. It works alongside a multidisciplinary team that is determined to convert the tide to one of the most void features and fatwas in cancer.
